CCM
REGN icon

Copernicus Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Copernicus Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,500
Closed -$710K – 16
2021
Q1 		$710K Buy
+1,500
New +$730K 11.47% 2

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Copernicus Capital Management's REGN Position: Q2 2021 in Review

Copernicus Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2021, closing a stake of 1,500 shares — an estimated $710K sold.

Copernicus Capital Management first reported a position in REGN in Q1 2021 and held it in 1 quarter. The position peaked at $710K in Q1 2021. 971 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

  • Copernicus Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 1,500 Regeneron Pharmaceuticals shares in Q2 2021, an estimated $710K.
  • Copernicus Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Copernicus Capital Management's Regeneron Pharmaceuticals position peaked at $710K in Q1 2021.
  • 971 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on Copernicus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.